Mycoplasma cynos is an emerging respiratory bacterium in dogs. It is associated with kennel cough and may lead to fatal pneumonia. This bacterium is very complex, and the lack of standardized diagnostic and knowledge on antibiotic therapy makes clinical management difficult. Since no vaccine is available, current treatment of M. cynos-associated outbreaks relies on antibiotics. However, the in vitro activity of antibiotics against M. cynos has never been studied and the effectiveness of antibiotic therapy for M. cynos disease is completely unknown. This may lead to unsuccessful treatment and antibiotic resistance.
In vitro testing of antibiotics is an urgent need to provide appropriate treatment, and to avoid inappropriate use of antibiotics. Unfortunately, these tests are very time-consuming for mycoplasmas, partially explaining the absence of information on M. cynos.
In this project, researchers will investigate the in vitro activity of antimicrobials against M. cynos isolated from dogs with respiratory disease, and implement the first genome-wide association study to identify genetic mutations linked to antibiotic resistance in M. cynos, which has never been investigated before. This will help develop genetic-based diagnostic assays for the rapid detection of resistant Mycoplasma isolates to better allow the results to inform clinical therapy. Results from this project will direct effective diagnosis and therapeutic interventions for an emerging respiratory disease in dogs.
Co-sponsored with the AKC Canine Health Foundation, Grant Number: 03053-A
Grazieli Maboni, DVM, MSc, PhD; University of Guelph